Skip to main content
Fig. 2 | BMC Endocrine Disorders

Fig. 2

From: A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus

Fig. 2

Variation in study variables over the 24-week study window for the mITT population. a Mean HbA1c (%). The analysis excluded measurements obtained >14 days after treatment cessation and for Week 24 (LOCF), the analysis included measurements obtained ≤14 days after the last dose of study medication. b Mean fasting blood glucose (mmol/l). The analysis excluded measurements obtained >1 day after treatment cessation. c Mean nocturnal blood glucose (mmol/l). The analysis excluded measurements obtained >1 day after treatment cessation. d Mean eight-point SMBG (mmol/l). Error bars represent the standard deviation. LOCF, last observation carried forward; SMBG, self-measured blood glucose

Back to article page